Abbott Laboratories (ABT): CFO bought ~$201K

~$201K

Approx. value · 2,200 sh @ $91.50

2,200

Holds after · shares reported

Traded

Apr 23, 2026

Filed

Apr 27, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
2. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
3. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
4. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
5. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
6. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
7. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
8. Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
9. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
10. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
11. Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
12. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
13. Apr 23, 2026 · this disclosureInsider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market

What came next

1. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
2. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
3. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
4. Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
5. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
6. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
7. May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
8. May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
9. May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
10. May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
11. May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
12. May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
13. Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
14. Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
15. Jun 17, 2026FDAFDA device clearance: Amplatzer TorqVue Exchange System
16. Jul 2, 2026FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
17. Jul 7, 2026Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
18. Jul 8, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
19. Jul 14, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
20. Jul 15, 2026FDAFDA device clearance: EnSite™ X EP System

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 6 Congress trade reports and 59 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Philip P Boudreau, EVP AND CFO

• SEC Form 4 at Abbott Laboratories (ABT)Aug 11, 2025

The full history of Philip P Boudreau, EVP AND CFO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Abbott Laboratories

• House Clerk periodic transaction reportOct 30, 2026
• House Clerk periodic transaction reportOct 27, 2026
• House Clerk periodic transaction reportOct 12, 2026
• SEC Form 4Sep 3, 2026
• SEC Form 144Sep 2, 2026
• SEC Form 4Aug 27, 2026

Everything OQRO holds on this company is on its ABT page.